Development of medicines for the treatment

of type 2 diabetes mellitus

Our approach
Innovative drug
Hypoglycemic drug with an original mechanism of action (first-in-class), it is an agonist of the GPR119 receptor, stimulates the secretion of incretins and insulin
Efficacy and safety
Due to the mechanism of action, Dipiaron causes physiological regulation of glucose level, demonstrating high efficacy and safety, and reduces the risk of complications
Convenient use
The oral route of administration provides ease of use for long-term treatment compared to injectable forms of other modern drugs
Based on experience and knowledge, we are developing an effective and safe treatment for type 2 diabetes mellitus that will improve the quality of life of many patients, preventing further development of the disease and its complications
About the product
Dipiaron is an oral agonist of the GPR119 receptor, which is a new validated target for T2DM therapy. Due to low systemic availability, it stimulates GPR119 in specialized L- and K-cells of the epithelium of the gastrointestinal tract.

It belongs to the group of modern drugs, such as GLP-1 analogues and DPP-4 inhibitors, which stimulate the production of incretins. The drugs of this group cause pleiotropic effects in the body: a decrease in the risk of cardiovascular complications of diabetes, endothelial, neuro- and cardioprotective effects
Dipiaron is an innovative highly effective non-injectable drug for the treatment of type 2 diabetes mellitus (T2DM), which helps to reduce the incidence of systemic side effects and complications of the disease.
Our site uses cookies, by staying on the page you agree to their use